Board of Directors
DR UWE SCHLOKAT
CEO & Director
Dr Uwe Schlokat received his Master’s degree and PhD in Molecular Biology from Heidelberg University, Germany.
In a biotech career that has spanned over 25 years, he has carried out research at Genentech Inc (US), product development at Immuno AG (Austria), to global project program management at Baxter Healthcare (Austria). During this period, Dr Schlokat published and filed over 50 publications and patents, predominantly in the area of recombinantly produced therapeutic agents.
In these different roles, he was responsible for driving new development or lifecycle products, including: ADVATE (recombinant FVIII), GAMMAGARD Liquid (plasma derived Immunoglobulins) and RIXUBIS (recombinant FIX) and was also involved in product development for devices such as BAXJECT II (reconstitution device) and vaccines such as ACAM 2000 (smallpox vaccine) for emergency stockpiling. In addition, Dr Schlokat’s team led the development of products such as recombinant von Willebrand Factor or Factor VIIa, currently in late Stage (Phase III) clinical development.
Prior to joining Sentinext Therapeutics as CEO, he was a member of the senior management team of Baxter Healthcare’s largest business unit – the Haemophilia Unit. During the later stages of his career with Baxter Healthcare, he headed the New Product Development teams and oversaw portfolio recommendations. As a member of the Business Unit’s senior management team, he was responsible for providing strategic direction for the company.
He has been a peer reviewer for international journals, and was also organiser of the 16th European Society for Animal Cell Technology (ESACT) Meeting 1999 in Lugano, Switzerland (the largest cell culture meeting in Europe), and the 2nd European Meeting of Cell Engineering (EMCE) 2001 in San Jorge, Spain.
In addition, he is a certified Project Management Professional (PMP) of the Project Management Institute, and holds an adjunct professorship in Biotechnology at the University of Applied Sciences/International Management Centre, Krems, Austria.
When time permits, he enjoys cultural travelling and outdoor activities such as skiing and trekking. He has climbed Mt Kilimanjaro on a few occasions and is looking forward to his next major trip with his sons.
Dr Ganesh Kishore
Malaysian Life Sciences Capital Fund (MLSCF) - Chairman
Dr Zainul Zainuddin
Malaysian Technology Development Corporation (MTDC)
Dr Thomas P. Monath
BioProtection Systems/NewLink Genetics Corp
Agensi Inovasi Malaysia (AIM)